Want to join the conversation?
$JNJ has a multitude of promising potential line extensions across every therapeutic area, approx. 40 in total, by 2019. Of this, 10 have more than $0.5Bil potential. Cumulatively, the line extensions for Xarelto and Invokana have the potential to drive $3-5Bil in incremental sales for the cardiovascular franchise.
$AVGO 4Q results beat analyst’s expectations again this time. Time to make some hay while the sun shines ;)
You are such a letdown $FII. I regret not selling you when you were nearing $33. Now I am stuck with you, you are stuck with me!
Can you imagine a food store with no cash registers? Well, it is coming true soon thanks to $AMZN. The company is opening its new grocery store in Seattle and it has no cash registers. AI takes over!